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INTRODUCTION 
 
 
Systemic Lupus Erythematosus (SLE) is an 
autoimmune disease with worldwide distribution and affects all 
races. It is more common in blacks and females, particularly of 
childbearing age.  
 
The sex distribution is 1:8 (♂ : ♀) in adults. It is a 
systemic disease with varied manifestations. It is diagnosed by 
the following criteria. 
 
1. Malar rash 
2. Discoid rash 
3. Photosensitivity 
4. Oral ulcers 
5. Non-erosive arthritis of two or more peripheral joints 
6. Serositis 
7. Renal disorder – Proteinuria > 0.5 g/day or cellular 
casts 
8. Seizures or psychosis without other causes 
9. Hemolytic anemia or leucopenia or lymphopenia or 
thrombocytopenia in the absence of offending drugs 
10. Presence of Anti-dsDNA, anti-Sm, and / or anti-
phospholipid antibodies 
11. An abnormal titer of ANA by immunofluorescence or an 
equivalent assay at any point in time in the absence of 
drugs known to induce ANAs. 
 
When 4 criteria are fulfilled, it is diagnostic of SLE.  It’s a 
systemic disease with significant morbidity. The manifestations 
are varied and differ from time to time. They change because of 
the disease activity itself or due to treatment. 
 
Cardiac involvement in SLE in relatively common. It may 
be transient or permanent. Pathologically, the pericardium, 
myocardium, endocardium and the coronary arteries may be 
involved.  
 
The patients with cardiac involvement are mostly 
asymptomatic. When symptomatic, they may have chest pain 
attributable to pericarditis. Anginal pain can occur at any age in 
SLE patient because of accelerated atherosclerosis due to long 
term steroid therapy or rarely due to coronary arteritis. 
 
Symptoms of congestive cardiac failure due to myocardial 
dysfunction or valvular disease include shortness of breath, 
pedal edema and fatigue. These can occur also due to anemia, 
renal and pulmonary involvement. 
 
Syncopal attacks due to conduction disturbances in SLE 
are quite rare. 
 
The symptoms subside or abate with steroid therapy 
proving the immunological basis of the cardiovascular 
involvement. 
 
Since many patients are asymptomatic, a thorough 
examination of the cardiovascular system by ECG, CXR and 
ECHO reveals hitherto silent pericarditis, valvular heart disease 
or myocardial dysfunction. 
  
  
 
 
AIMS AND OBJECTIVES 
 
 
 
 
 To study the various cardiac manifestations in SLE 
 
 To know the incidence of cardiac involvement in SLE in the 
study group 
 
 To know the common cardiac manifestations in the study 
group 
 
REVIEW OF LITERATURE 
 
 
 
Cardiac abnormalities are one of the most important 
clinical manifestations of Systemic Lupus Erythematosus 
(SLE), contributing significantly to the morbidity and mortality 
of this disease. Including arterial hypertension, cardiac 
involvement has been reported in from 52 to 89% of patients 
(1-5). The pathologic picture is that of a pancarditis affecting 
the pericardium, myocardium, endocardium and coronary 
arteries. Involvement of one layer of the heart, such as a 
pericarditis, may dominate the clinical picture in one patient, 
whereas in another, the heart may be diffusely affected. 
 
At times, it is difficult to differentiate between primary 
cardiac charges resulting from SLE and those resulting from 
complicating conditions. Frequently occurring symptoms that 
are referable to the heart and the cardiovascular system must 
be carefully evaluated and differentiated from non cardiac 
symptoms, which they can mimic. Symptoms of angina 
pectoris, hypertension, cardiac failure and pericarditis 
frequently mimic those of esophageal spasm, reflux esophagitis, 
pleurisy, pneumonitis, and costochondritis. The prevalence of 
cardiovascular abnormalities in SLE has been based mostly on 
retrospective material or on highly selective series of patients. 
A prospective study of cardiovascular disease in all adult 
patients with lupus living within a defined area in southern 
Sweden over a mean period of 5.6 years was completed (6). A 
high frequency of pericarditis (35%), valvular heart disease 
(27%), mild pulmonary hypertension (16%), and decreased left 
ventricular function (19%) was found. Ischemic heart disease 
was observed in 17%. 
 
PERICARDITIS 
 
Pericarditis is diagnosed in proportion to the care of the 
examination.  
 
 Involvement of the pericardium in SLE, which was first 
recognized by Keefer and Felty (7) in 1924, is a common 
feature, and it is the most common cardiac abnormality in this 
disease. In several reported series, the prevalence of 
pericarditis has ranged from 6 to 45%. Godeau et al. (8) 
diagnosed pericarditis in 27% of 112 patients, and Rothfield 
(9) diagnosed pericarditis in 25% of more than 200 patients. 
Doherty and Seigel (10) found the prevalence of pericarditis 
to be 25.6% among 1194 patients with SLE who were collected 
from several clinical series in the literature. In contrast, they 
found a prevalence of 62.1% among 254 autopsy cases, 
indicating that asymptomatic pericardial involvement is 
common. Moreover, the diagnosis may be missed unless the 
patient is specifically questioned about its clinical 
manifestations. Introduction of echocardiography as a 
diagnostic modality has confirmed the high frequency of 
asymptomatic pericardial effusion and thickening in patients 
with SLE. 
 
 Acute pericarditis may occur as an isolated finding or as 
part of a generalized serositis. Estes and Christian (11) noted 
cardiac manifestations in 38% of their 150 patients. Pericarditis 
occurred in 29 patients and was associated with pleural 
effusions in all but 7. 
 
 The clinical picture of lupus pericarditis usually is typical, 
with complaints of substernal or pericardial pain aggravated by 
motion such as breathing, coughing, swallowing, twisting and 
bending forward. At times, a pericardial rub may be heard in an 
asymptomatic patient. Symptoms may be severe and persistent 
or mild and transitory. Complaints may last for hours or weeks, 
and they often recur over a period of years. Pericarditis usually 
develops during the subacute or chronic period. 
 
 M-mode and two dimensional (2-D) echocardiography are 
the current methods of choice for diagnosing pericardial 
effusions. Ito et al. (12) found effusions in 46% of 48 selected 
patients with SLE undergoing echocardiography. Bomaski et 
al. (13) noted effusions in 49% of 47 patients, and Chia et al. 
(14) described effusions in 24% of 21 unselected patients. 
Using both M-mode and 2-D echocardiography, Doherty et al. 
(15) found pericardial effusion in 42% of 50 patients with SLE 
who were studied retrospectively. 
 
Recent studies have compared the echocardiographic 
findings in unselected patients with SLE with those in age and 
sex-matched healthy controls. Klinkoff et al. (16) found 
pericardial involvement in 10 of 47 patients with SLE (21%) and 
in none of 46 healthy controls. Effusion was present in 4 
patients and pericardial thickening in 6. Crozier et al. (17) 
found pericardial effusion in 27 of 50 Chinese patients with SLE 
and in 5 of 50 matched controls, with the significantly larger 
effusions in the patients with SLE. Cervera et al. (18) found 
effusion in 19 of 70 patients with lupus (27%) and in none of 40 
matched controls. Five patients (7%) with severe to moderates 
effusions had clinical and ECG features of pericarditis. In 
contrast, 14 patients (20%) with small effusions did not have 
clinical pericarditis. 
 
Cardiac Tamponade 
 
Despite the high frequency of pericarditis and effusion, 
cardiac tamponade rarely occurs in SLE. It may develop at any 
point during the course of the disease, however, and should be 
considered in patients with signs of venous congestion. 
 
Of 150 patients with SLE who were followed prospectively 
by Estes and Christian (11), 29 developed pericariditis, and 
only 2 of these developed cardiac tamponade that required 
pericardial fenestration. The prevalence of cardiac tamponade 
was 0.8% in a combined series of 15 studies consisting of 1332 
patients with SLE (10). A retrospective study of 75 patients with 
lupus and pericarditis (19) found 11 episodes of cardiac 
tamponade in 10 patients (13%). Tamponade was the 
presenting manifestation of SLE in 4 patients, and the 
remaining 7 episodes occurred during the active phase of the 
disease. Tamponade was fatal in one patient. Cardiac 
tamponade has been reported as the initial manifestation of the 
disease in a few pediatric and adult cases, as well as in late-
onset SLE . 
 
Constrictive Pericarditis 
 
Constrictive pericarditis results from chronic fibrous 
thickening of the wall of the pericardial sac, causing impairment 
of normal diastolic filling of the heart . Only very few cases of 
constrictive pericarditis resulting from SLE have been described 
(20). All reported cases, except one, were males. Male 
predominance also is observed in constrictive pericarditis 
resulting from other causes . The condition developed while 
patients with lupus on systemic corticosteroids, and pathologic 
findings included hyalinized fibrotic thickening of the 
pericardium and perivascular mononuclear infiltrates . 
Constrictive pericarditis also has been seen in patients with 
drug-induced LE resulting from procainamide and from 
hydralazine (21). 
 
MYOCARDITIS 
 
 Primary myocardial involvement in SLE is uncommon. 
 
 Myocarditis was diagnosed clinically in 8% of 520 patients 
by Dubois (22), in 8% of 150 patients by Estes and Christian 
(13), and in 10% of 128 patients by Ropes (23). Borenstein et 
al. (24) found 5 cases of myocarditis in 140 patients with SLE 
who were reviewed retrospectively for myocardial disease. In a 
prospective study of 100 patients with SLE for cardiovascular 
manifestations, myocarditis was diagnosed in 14% (25). 
 
The clinical picture of SLE myocarditis is similar to that of 
myocarditis resulting from viral infection or some other cause. 
The earliest change usually is tachycardia, which is 
disproportional to the fever. The heart becomes diffusely 
enlarged, often with the point of maximal impulse at the 
anterior axillary line. The patient may have dyspnea, 
palpitations, heart murmurs, sinus tachycardia, ventricular 
arrhythmias, gallop rhythm, and/or congestive heart failure. 
The diagnosis of SLE myocarditis often is difficult to make 
clinically, because other factors that can lead to congestive 
heart failure such as anemia, uncontrolled hypertension, 
systemic infection, valvular disease, or fluid and salt retention 
resulting from renal disease or systemic corticosteroid use, also 
may be present. 
 
At autopsy, SLE myocarditis is diagnosed more frequently 
than is reported in clinical series. Among 236 autopsied SLE 
cases that were collected by Doherty and Siegel (10) from 
eight separate reports, myocarditis was found in 100 (40%). 
The pathological abnormalities vary in severity, usually 
consisting of small foci of interstitial plasma cell and lymphocyte 
infiltrates and, rarely, of a widespread, diffuse, interstitial 
inflammation, fibrinoid change and hematoxylin bodies are 
seen. Small foci of patchy myocardial fibrosis are common in 
corticosteroid-treated patients. 
 
MYOCARDIAL FUNCTION ABNORMALITIES  
AND CONGESTIVE HEART FAILURE 
 
  
 Myocardial function abnormalities are frequently found in 
patients with SLE, even in those without cardiac symptoms. 
 
 Strauer et al. (26) studied cardiac hemodynamics during 
right and left-heart catheterization in five young, female 
patients with SLE and without clinical symptoms and signs of 
cardiac disease. Evidence of impaired pump function, reduced 
contractility, increased myocardial wall stiffness, and decreased 
coronary artery reserves were found. It was suggested that 
lupus cardiomyopathy may affect intrinsic contractile properties 
of the myocardium and frequently may occur subclinically. 
 
 Del Rio et al. (27) compared systolic time intervals, a 
noninvasive method that is helpful in assessing myocardial 
function, in 25 patients with SLE and 22 healthy controls. The 
patients had shorter left ventricular ejection times and longer 
pre-ejection periods than the controls, suggesting impaired left 
ventricular systolic function. These abnormalities were 
independent of age, duration of SLE, blood pressure, anemia, 
renal disease, steroid treatment and immunologic activity. 
 
Crozier et al. (17) reported that compared to healthy 
controls, patients with SLE have significantly decreased left 
ventricular ejection fractions and diastolic compliance and 
increased left ventricular systolic dimensions. These 
abnormalities were not explained on the basis of hypertension 
or coronary artery disease, suggesting primary myocardial 
involvement. 
 
 Studying a group of patients with lupus and stable 
disease, Enomoto et al. (28) found normal left ventricular 
systolic functions but decreased left ventricular diastolic 
function, which appeared to worsen progressively with age. 
Diastolic dysfunction can result from hypertension, steroid 
therapy, or primary myocardial involvement by SLE. However, 
the presence of diastolic dysfunction in young normotensive 
patients with lupus on a short duration of steroid therapy 
suggest that the latter mechanism is responsible for the 
myocardial abnormality. 
 
Newer techniques, including radionuclide ventriculography 
confirms the high prevalence of left ventricular dysfunction in 
SLE. The abnormalities are subclinical, however, and whether 
these are clinically significant over time has not been fully 
investigated in prospective studies. Recently, Winslow et al. 
(29) reported abnormalities in systolic and diastolic left 
ventricular function to be progressive over time, leading to a 
decline in ventricular function and an increase in left ventricular 
mass and size. In contrast to the findings of other investigators, 
they found that these abnormalities were related to 
hypertension and coronary artery heart disease. In 
normotensive patients with lupus, mild functional abnormalities 
(Presumably resulting from SLE) did not worsen during a 5 year 
observation period. This important study suggests that primary 
involvement of the myocardium in SLE does not commonly (by 
itself) lead to clinically significant changes in left ventricular size 
and function, and that other pathogenetic factors, especially 
hypertension and atherosclerosis, are more important. 
 
 Decreased left ventricular function was noted by Sturfelt 
et al. (6) in 14 of 75 patients with lupus (19%) who were 
followed prospectively. Five had myocardial infarction, and in 
the remaining 9, who had no clinical evidence of myocardial 
infarction, left ventricular dysfunction was mild. Thus, this study 
confirms that severe global left ventricular hypokinesia is not a 
common feature of SLE. 
 
Effect of treatment on Myocardial Function 
 
 Myocardial function in a group of patients with SLE and 
active disease was assessed before the initiation of 
corticosteroid therapy and when the illness became inactive 
following steroid therapy. Using computer-assisted analysis of 
digitized echocardiograms, Murai et al. (30) found evidence of 
left ventricular systolic and diastolic dysfunction that reversed 
with treatment. 
 
 Thus the data from various noninvasive studies 
consistently indicate that abnormalities in myocardial function 
are common in patients with SLE and active disease, even in 
the absence of overt cardiac symptoms. That these 
abnormalities reverse with steroid therapy supports an 
immunologic basis for the myocardial dysfunction. 
 
Congestive Heart Failure 
 
 The clinical diagnosis of congestive heart failure in SLE is 
often difficult, because manifestations of activity of the 
underlying disease can mimic the symptoms of cardiac failure. 
Failure often is preceded by fever, tachycardia, hepatomegaly, 
and hypertension associated with nephropathy. Corticosteroid 
therapy can aggravate these processes. Dyspnea resulting from 
pleuritis, ascites, or primary diaphragmatic dysfunction, other 
factors that may contribute or aggravate congestive heart 
failure, such as valvulitis, myocarditis, pericarditis with effusion, 
and anemia, often are present. Because they may coexist, it 
often is difficult to ascertain how much of the patient’s dyspnea 
and other symptoms result from cardiac decompensation and 
how much result from other manifestations of the disease. 
 
Congestive heart failure was diagnosed clinically in 5% of 
Dubois’s 560 patient (22) and in 11% of Estes and 
Christian’s 150 patients (11). Of 100 patients with SLE who 
were followed prospectively by Badui et al. (25) for cardio 
vascular manifestations, 10 developed congestive heart failure. 
This was associated with myocarditis in 5 patients, hypertension 
in 4, and vascular heart disease in 1. Congestive heart failure 
occurred in 10 of 142 patients. (7%) reported by Hejtmancik 
et al. (20), and myocarditis was the major cause of heart 
disease in 6. All 5 patients who succumbed to heart failure had 
pathologic evidence of myocarditis at autopsy. In contrast, 
Brigden et al. (2) diagnosed cardiac failure in 22 of 60 
patients with SLE, and hypertension was the major cause. 
Rarely, however, was it the sole responsible factor. 
Decompensation with a low or normal blood pressure developed 
in 5 patients, 3 of whom had pericarditis and 1 of whom 
bacterial endocarditis. Myocarditis as the sole cause of cardiac 
failure was not seen in any of these patients. 
ENDOCARDITIS AND VALVULAR HEART DISEASE 
 
Libman-Sacks “atypical verrucous endocarditis,”  is 
the most characteristic and classic cardiac lesion of SLE, 
comprised of verrucous vegetations that range from 1 to 10 
mm in diameter. Grossly, the verrucae appear as “granular, 
tawny or pinkish, pea-sized masses densely adhered to the 
underlying endocarduim and formed single or conglomerate and 
sometimes mulberry-like clusters”. The lesions are found near 
the edge of the valve, on both surfaces of the valves, on the 
rings and commissures, and less frequently, on the chordae 
tendinea, papillary muscles, and atrial and ventricular mural 
endocardium . The vegetations can develop in any valve and 
often are multivalvular. Libman and Sacks (31) as well as 
Gross (32) noted the verrucae most commonly in the tricuspid 
valve, but more recent studies have found a higher frequency 
on the mitral valve (4), especially in the recess between the 
posterior valve leaflet and the ventricular wall . 
 
 The diagnosis of Libman-Sacks endocarditis can only be 
made with certainity at autopsy or at surgery. The prevalence 
of these lesions varies greatly among autopsy series ranging 
from 13 to 74%. Before the availability of steroids, Doherty 
and Siegel (10) found a prevalence of 59% among 86 autopsy 
cases reported in the literature. In contrast, 35% of 236 
autopsy cases reported after 1953 who had received steroids 
had Libman-Sacks verrucuous lesions. 
 
 Another explanation for the decreasing prevalence may be 
that the endocardial lesions formerly were considered to be a 
requisite to the diagnosis, because these constituted the most 
specific gross postmortem findings, whereas the diagnosis of 
SLE now is made primarily on clinical grounds. Thus, the latter 
series would not be weighted in favour of endocardial 
involvement. 
 
The clinical diagnosis of Libman-Sacks endocarditis is 
difficult. Physical findings and echocardiographic abnormalities 
may suggest the diagnosis, but they are not diagnostic. Many 
patients with active SLE have tachycardia, anemia and fever, all 
of which may be associated with a cardiac murmur. Thus, it 
often is difficult to interpret the significance of murmurs, even if 
they are of greater intensity.  
Libman-Sacks endocarditis rarely produces hemodynamic 
changes, but it has been associated with ruptured chordae 
tendineae, aortic stenosis, thromboembolic disease , and 
cerebral emboli . Rarely, Libman-Sacks vegetation may mimic a 
large intracardiac tumor.  
 
Valvular Heart Disease. 
 
 It now is recognized that hemodynamically and clinically 
significant valvular disease occurs in patients with SLE and may 
require prosthetic valve replacement. Aortic insufficiency 
represents the most commonly reported lesion . Doherty and 
Seigel (10) collected 36 cases in  the English literature and 
concluded that the insufficiency probably results from multiple 
factors, including Libman-Sacks endocarditis, fibrinoid 
degeneration causing thinning and fenestration of the valve 
cusps, distortion of the valve tissue by fibrosis, valvulitis, 
bacterial endocarditis, aortitis, and aortic dissection. They 
identified systemic hypertension, steroid therapy, bicuspid 
aortic valves and rheumatic fever as risk factors in some of the 
patients. 
 
 Few cases of significant isolated mitral insufficiency or of 
combined mitral and aortic insufficiency have been described in 
patients with SLE. Bulkley and Roberts (33) have suggested 
that steroid therapy leads to the healing of verrucae and fibrous 
scarring. The posterior mitral leaflet and its chordae tendineae 
become shortened and adhere to the underlying mural 
endocardium, causing mitral regurgitation. Other causes include 
fibrinoid necrosis of the papillary muscles and rupture of the 
chordae tendineae .  
 
 Color Doppler echocardiography has shown a high 
frequency of valvular regurgitation in SLE, with right-sided 
regurgitation being more common than left-sided regurgitation. 
Right-sided regurgitation may be related to pulmonary vascular 
lesions causing increased pulmonary artery pressure (34).  
 
 
 
Infective Endocarditis 
 
 Libman-Sacks endocarditis may be complicated by 
infective endocarditis.  An analysis of 15 reports by Doherty 
and Siegel (10) showed that 4.9% of Libman-Sacks 
endocarditis cases diagnosed at autopsy and 1.3% of clinically 
diagnosed cases were complicated by infective endocarditis. 
Bacterial endocarditis was diagnosed in 6 of 571 patients with 
SLE who were admitted to the National Institutes of Health 
(NIH) and in 2 of 142 patients seen by Ropes (23). In the NIH 
study, all 6 patients were treated with corticosteroids, and 4 
had pre-existing heart murmurs. Endocarditis occurred after 
dental procedures in 2 patients and for no known cause in 4. 
Endocarditis was diagnosed in 1% of patients with SLE, which is 
a greater percentage than that of any other connective tissue 
disease seen at the NIH. Antibiotic prophylaxis is recommended 
before operative dental or other surgical procedures in all 
patients with SLE. The need for prophylaxis is further supported 
by the disproportionately high frequency of mitral valve 
prolapse in SLE diagnosed by echocardiography. 
 
Coronary Artery Disease and Myocardial Infarction 
 
 The prevalence of coronary artery disease (CAD) and or 
myocardial infarction in patients with SLE appears to be 
increasing. The occurrence of myocardial infarction in female 
patients with lupus younger than 35 years of age has been 
reported (10). 
 
 Different mechanisms, acting either solely or in 
combination, are implicated in the pathogenesis of CAD and 
myocardial infarction in patients with SLE. Atherosclerosis, a 
pathologic process that is accelerated by long-term 
corticosteroid use, is by far the most common. Vasculitis 
involving the extramural coronary arteries and resulting in 
luminal occlusion is another such cause, although this is rare. 
Other mechanisms include coronary arterial spasm and acute 
coronary artery obstruction from an insitu thrombus or 
embolus. 
 
 In an authoritative study of risk factors for CAD, Petri et 
al. (35) found CAD in 19 of 229 patients with SLE (8.3%) who 
were studied longitudinally. They also identified independent 
risk factor for CAD: Older age at diagnosis of SLE, hypertension, 
hypercholesterolemia, duration of SLE, obesity, and duration of 
steroid therapy. Over a period of 3 years, CAD accounted for 
30% of all deaths in their patients. More important, they found 
that cardiac risk factors were very prevalent in their lupus 
patient population, whose average age was only 38.3 years. 
Three or more known risk factors were identified in 53% of their 
patients, even in those who were not on steroid therapy during 
the study, yet only 17% of their patients were aware that they 
were at risk for developing CAD. Regression analysis showed 
that an increase in prednisone dose of 10 mg daily was 
associated with significant changes in serum cholesterol, blood 
pressure and body weight. They also found that 
hydroxychloroquine therapy was associated with lower serum 
cholesterol, suggesting an additional benefit from this agent. 
 
Myocardial infarctions have been reported in patients with 
SLE less than 35 years of age, and even as young as 5 years . 
In 1982, Homey et al. (36) described six cases of ischemic 
heart disease in patients SLE aged 15 to 29 years. Of these 
patients, three patients had atherosclerotic lesions, and one 
was helped by coronary artery bypass surgery. Coronary 
arteritis was found in three patients; one of these was 
diagnosed during life and benefited from systemic 
corticosteroids. 
 
ECG changes and Conduction defects 
 
The ECG records can be useful in the diagnosis and 
treatment of patients with SLE. It is of particular value in 
equivocal cases, in whom the tracing shows changes suggestive 
of pericarditis or myocarditis that are not apparent by history 
and physical examination, thereby alerting the clinician to 
evaluate carefully for evidence of multisystem disease. The ECG 
may show abnormalities that are caused by electrolyte 
imbalance, which are not uncommon in patients with renal or 
cardiac disease who are receiving corticosteroids and /or 
diuretics. 
 Abnormal ECGs often are found in patients with SLE, but 
no changes actually are considered to be characteristic of the 
disease (5). Abnormal tracings were found in 34% of 291 
patients by Dubois (22) and in 74% of 100 female patients 
with SLE who were followed by Badui et al. (25) specifically for 
cardiovascular disease. Differences in patient selection, 
frequency of obtaining in ECG, and other factors probably 
account for the wide variation in the prevalence of 
abnormalities. 
 
Conduction Defects 
 
Conduction defects and rhythm disturbances are not 
uncommon in patients with SLE. The prevalence is not known, 
although it seldom has been reported to be more than 10%. 
Studies using constant ECG monitoring  are not available. 
Different type of abnormalities have been described, including 
bundle-branch block, atrioventricular block, complete heart 
block, and atrial premature contraction. First-degree heart block 
is uncommon in patients with SLE; it is more characteristic of 
acute rheumatic fever. However, occasional patients with first-
degree block in SLE have been reported (3, 4, 25). 
 
 
 
Persistent Tachycardia 
 
 Estes and Christian (13) observed persistent sinus 
tachycardia in the absence of fever or other manifestations of 
heart disease in 19 of 150 patients. This often presents a 
clinical problem in management if the patient is otherwise 
asymptomatic. 
 
 Echocardiography and other noninvasive cardiac 
laboratory tests are indicated to exclude myocardial 
dysfunction. Increasing the dosage of steroids may suppress 
the tachycardia in some patients. In the absence of other 
evidence of cardiac disease, however, it may be necessary to 
use a steroid dose that partially controls the tachycardia but 
has no excessive side effects. β-Blockers such as propranolol 
may be helpful in patients with symptomatic sinus tachycardia. 
 
Hypertension 
 
Arterial hypertension is a common feature of SLE. Blood 
pressure readings of more than 140/90 mm Hg were found at 
some time in the clinical course in 25% of Dubois’ 520 patients 
(22). The mean prevalence of hypertension in nine published 
series of SLE patients is 28.8% (range, 12-49%) 
 
Hypertension was reported to be less prevalent in patients 
with SLE and rheumatoid-like polyarthritis, especially in those 
without nephritis and in blacks . It is speculated that the 
“protective” effect of the polyarthiritis is conferred by a higher 
frequency of the DR4 allele. 
 
Hypertension in SLE is related to the development of 
nephropathy and to the use of systemic corticosteroids. In 
1948, Humphreys (37) suggested that in the absence of renal 
disease, the blood pressure in patients with SLE is normal or, 
more often, low. 
 
Subsequent investigators have confirmed the frequent 
association between hypertension and renal disease in SLE. 
Brigden et al. (2) reported that of 26 hypertensive patients 
with SLE in their series, 20 had renal disease, 2 had incidental 
essential hypertension, and the remaining 4 developed 
hypertension while on systemic corticosteroids. A retrospective 
analysis of 232 patients with SLE at the NIH revealed that 
hypertension occurs early during the course of SLE in many 
patients, and that it is not necessarily associated with clinical 
severe renal disease (38). Two-thirds of the hypertensive 
patients with SLE had a creatinine clearance of more than 60 
mL/min and nonnephrotic-range proteinuria. Moreover, only 
60% of these patients with biopsy proven diffuse 
glomerulonephritis were hypertensive. Normotensive patients 
with SLE tended to be on a lower dosage of corticosteroids than 
the hypertensive patients, but considerable overlap occurred 
between the two groups.  
 
Hypertension is a frequent finding in patients who are 
taking systemic corticosteroids for asthma, SLE, and other 
diseases. The hypertension probably results from several 
mechanisms, including fluid and sodium retention, increased 
sensitivity to endogenous catecholamines and increased 
production of angiotensinogen. 
 Long-standing hypertension can lead to the development 
of myocardial hypertrophy in patients with SLE. Although 
hypertension is a major factor in the pathogenesis of congestive 
heart failure in SLE, it rarely is the only cause. Other 
predisposing factors often are present, such as anemia, 
myocarditis, pericarditis, infection, and corticosteroid use. 
 
Ginzler et al. (39) showed that hypertension occurring at 
any time during the course of SLE is a risk factor for 
deterioration in renal function and for renal death, and that is 
independent of steroid therapy and active nephritis. The high 
proportion of black patients, who are known to have a higher 
prevalence of hypertension, may have contributed to the 
outcome of this study. 
 
Effect of Corticosteroids on the Heart in SLE 
 
Long-term use of systemic corticosteroids for the 
treatment of SLE can result not only in an increased prevalence 
of hypertension, left ventricular hypertrophy, and congestive 
heart failure but also in other important changes in the heart.  
 In the steroid-treated patients, the Libman-Sacks 
endocardial lesions were smaller, fewer in number, and involved 
single rather than multiple valves. The mitral valve was most 
commonly involved in the steroid-treated patients and the 
lesions showed evidence of partial or complete healing. 
 
 The pericardium in nonsteroid-treated patients showed 
active fibrinous changes. In contrast, steroid-treated patients 
most commonly showed a fibrous (i.e., healed) pericarditis and, 
occasionally, infective pericarditis. The focal lesions of lupus 
myocarditis were found less frequently in the steroid-treated 
patients. Steroid-treated patients with SLE showed increased 
amounts of epicardial fat and intramyocardial fat, especially in 
the right ventricle, probably analogous to the deposition of 
subcutaneous adipose tissue in the face and upper back. Finally, 
steroid-treated patients showed a greater degree and frequency 
of narrowing of extramural coronary arteries by atherosclerotic 
plaques, leading to significant ischemic heart diseases. 
 
 
CARDIAC ABNORMALITIES AND  
ANTICARDIOLIPIN ANTIBODIES 
  
 The presence of cardiac abnormalities in SLE is strongly 
associated with increased levels of anticardiolipin antibodies. 
The sensitivity and specificity of high levels of anticardiolipin 
antibodies in the prediction of cardiac abnormalities is 78% and 
74% respectively. Nihoyannopoulos et al (40) demonstrated 
high levels of  anticardiolipin antibodies in 50 cases of SLE of 
which 39 had had atleast one cardiac abnormality. 
 
Chest Pain 
 
Chest pain is a frequent complaint of patients with SLE. 
The evaluation of such a patient is based on the same principles 
that are followed for any patient presenting with acute or 
chronic chest pain. A thorough clinical history and careful 
physical examination are the cornerstones of the diagnostic 
process. Certain clinical entities, however, should be 
remembered when formulating the differential diagnosis of 
chest pain in SLE, because these conditions may be relatively 
more prevalent in these patients. 
 
 
Cardiac Causes 
 
Acute lupus pericarditis probably is the most common 
cause of chest pain of cardiac origin in patients with SLE. The 
patient may present with the typical retrosternal pain that 
builds in intensity; is aggravated by lying down, swallowing, 
and/or inspiration ; and eases with sitting and leaning forward. 
Concomitant pleurisy often is present. Angina pectoris should 
be considered, even in a young female, because long-term 
steroid therapy can lead to accelerated atherosclerosis and 
CAD. Although rare, arteritis of the extramural coronary arteries 
can develop, resulting in myocardial infarction. Other cardiac 
causes include chest pain that is associated with mitral valve 
prolapse, which appears to be more prevalent among patients 
with SLE. 
 
 Pleurisy, with or without effusion, is one of the most 
common intrathoracic causes of chest pain in patients with SLE. 
Pleurisy may not necessarily be a result of the underlying 
disease but of tuberculosis or other infections. Bacterial 
pneumonia can present with pleuritic or nonpleuritic chest pain. 
Pulmonary embolism should be considered in the differential 
diagnosis of acute chest pain, particularly in those with 
antiphospholipid antibody syndrome. It must be stressed that 
pulmonary embolism may occur even in patients who test 
negative for aCL antibodies or lupus anticoagulant. Less 
frequent causes of chest pain include diffuse spasm and other 
esophageal abnormalities as well as pulmonary arterial 
hypertension. Patients on aspirin or other NSAIDs and 
corticosteroids are prone to gastritis and peptic ulcer disease, 
and when complicated by esophageal reflux, epigastric and 
retrosternal pain may develop. 
 
 Pain arising from musculoskeletal structures should be 
specifically sought. Costochondritis and fibromyalgia are not 
uncommon in patients with SLE, and both conditions are 
characterized by thoracic or chest wall pain (6). The examiner 
should palpate for tender points in the upper chest, trapezius, 
and infrascapular regions. Osteoporosis complicating chronic 
steroid therapy predisposes to rib fractures and vertebral body 
collapse. 
 
 Renal vein thrombosis in a patient with lupus nephritis and 
nephritic syndrome may present with pleuritic chest pain. 
 
 In choosing the laboratory investigations that are needed 
to evaluate an individual patient, the clinician should be guided 
by the clinical history and physical findings. A chest radiograph, 
ECG, and echocardiogram are helpful when intrathoracic causes 
of chest pain are being considered. The laboratory diagnoses of 
acute pulmonary embolism, angina pectoris, myocardial 
infarction, and chronic pain associated with esophageal 
abnormalities are basically the same in patients with lupus as in 
other patients without SLE. When exacerbation of the 
underlying disease is suspected, serologic markers of disease 
activity, such as anti-dsDNA and serum complement levels 
should be obtained. Evidence of other organ involvement should 
be sought. Tests for aCL antibodies and lupus anticoagulant are 
helpful in those patients with thromboembolic disease and 
valvular heart disease. 
MATERIALS AND METHODS 
 
 
 
 SLE patients(those patients who met 4 or more of the  
Classification Criteria for the diagnosis of SLE) in GGH – 
outpatient or inpatient in various wards of medicine, 
rheumatology and nephrology were assessed for cardiac 
symptoms and signs.  
 
 ECG, CXR and ECHO was performed in all these patients. 
HRCT was done in selective patients. 
 
 All patients were  
 
- questioned for the symptoms of chest pain, 
syncope, palpitations, dyspnea 
 
- examined for pulse, BP, intensity of S1, S2, the 
presence of murmurs, pericardial rub, S3 
 
- ECG was analysed for sinus tachycardia, 
arrhythmias, heartblock, features of 
pericarditis, hypertensive changes and 
Ischemic heart disease. 
 
- CXR was analysed for cardiomegaly, pleural 
effusion, pulmonary hypertension, 
reticulonodular shadows and peripheral wedge 
shape capacities. 
 
- ECHO was done to evaluate  
(1) Presence of pericardial effusion, 
thickening 
(2) Chamber dilatation, hypertrophy, 
presence of myocardial dysfunction – Systolic 
or diastolic 
(3) Valvular lesions 
(4)  Presence of vegetations. 
 
 
 
 
 
 
INCLUSION CRITERIA 
 
Patients who met atleast 4 of the 11 classification criteria for 
the diagnosis of SLE were included in the study. 
 
EXCLUSION CRITERIA 
 
Patients with clinical features of mixed connective tissue 
disorders    
   
 OBSERVATION 
 
 
The study group included 45 patients. There were 41 
females and 4 males patients. The ratio of female to male is 
10:1. The age distribution range from as low as 14 years to 
upto 40 years, with the majority being young adult females of 
reproductive age group. 
 
Of the 45 patients, only 15 had symptoms referable to 
cardiovascular system, when confounding factors like fever, 
anemia, pleurisy, renal failure were excluded as the cause of 
symptoms. This amounted to 33% of total patients.  
 
The common symptoms in decreasing order of frequency 
are furnished in table below: 
 
Symptoms Frequency 
Exertional dyspnea 8 
Palpitations – Paroxysmal, Regular 7 
Chest Pain – More of pericarditis like 
pain 
5 
Pedal edema – in patients with 
congestive cardiac failure 
3 
 
Clinical examination revealed the following signs in 
decreasing order of frequency 
 
Signs Frequency 
Hypertension (SBP>= 140, DBP>=90mm 
Hg) 
6 
Pericardial rub 4 
Elevated JVP 4 
Tachycardia 4 
Bibasal fine inspiratory crepitations 4 
Systolic murmur in the apex 2 
Midsystolic ejection click in the Mitral Area 2 
S3 1 
Loud P2 1 
 
 
ECG tracings were normal in 25 patients of our study. Of 
the remaining 20 patients, Sinus tachycardia was present in 15 
patients. The other findings were 
 
LVH 2 
T inversion in inferior leads 2 
Low Voltage complexes 1 
Poor progression of R wave 1 
Diffuse ST – T changes 1 
Incomplete RBBB 1 
 
CXR revealed cardiomegaly in 7 patients, pleural effusion 
in 2 patients and prominent Main Pulmonary artery in 1 patient. 
 
ECHOcardiogram was able to identify cardiac lesions in 24 
of the 45 patients. The findings in decreasing order of 
occurrence are  
 
Pericardial effusion 12 
MVP 11 
MR 8 
LVH 3 
AR 2 
Global Hypokinesia 2 
Regional hypokinesia 1 
TVP 1 
TR 1 
Diastolic dysfunction 1 
PHT (moderate) 1 
 
 
Of the total 45 patients, 24 had evidence of cardiovascular 
involvement.  
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DISCUSSION 
 
 
 
In the study group of 45 patients, 18 patients had no 
manifestations of cardiovascular system. 
 
27 patients (i.e.,) 60% of patients in the study group had 
one or more of the cardiovascular manifestations. 
Cardiovascular involvement has been reported in 52 to 89% of 
patients in study by Brigden W et al (2) and by Shearn M. A 
(5) 
 
Pericarditis 
 
In the study, 12 patients had evidence of pericarditis 
proven by ECHO. They had mild to moderate pericardial 
effusion. This accounted for 27% of total cases. Pericarditis has 
been reported to be the most common manifestation of SLE 
with a prevalence of 6 to 45 % in various studies by Godeau et 
al. (8).  Rothfield et al (9) and Siegel(10) found the 
prevalence to be around 25% in their studies. 
 
Of these two had evidence of polyserositis in the form of 
pleural effusion and/or ascites. In one patient it was a part of 
pancarditis. None of the patients had frank renal failure, since it 
was carefully avoided to prevent confusion regarding the 
etiology of pericarditis. 
 
 Five of our patients had chest pain that could be attributed 
to pericarditis. Four patients had pericardial rub on auscultation. 
So less than 40% of patients had clinical evidence of pericarditis 
and majority were asymptomatic. 
 
 There were no cases of tamponade or constrictive 
pericarditis in the study group. Both of them are rare as 
reported by Estes and Christian(11). 
 
Myocarditis 
 
In the study group, 4 patients had myocardial 
dysfunction; approximately 9% of the group. 2 patients had 
global hypokinesia and 1 patient had regional hypokinesia of 
anterior wall. The fourth patient was a hypertensive and had 
grade I diastolic dysfunction. 
  Several studies have shown that primary myocardial 
involvement is uncommon. Studies by Dubois(22), 
Borenstein et al. (24) have shown the prevalence of 
myocarditis between 8 to 14%. 
 
Winslow et al. (29) concluded that primary myocardial 
involvement in SLE is not commonly associated with significant 
clinical changes in left ventricular size and  function and other 
pathogenic factors like hypertension and atherosclerosis are 
more important.  
 
 In this group, one patient’s (patient no.13) first 
manifestation of the disease was cardiac failure, ECHO 
demonstrating global hypokinesia and EF of 43%. The patients 
symptoms and cardiac function markedly improved, when 
steroids were added to anti-failure medications.  
 
 Another patient (patient no.14), a 29 year old female was 
evaluated for pulmonary hypertension in the department of 
cardiology. She was referred to the department of medicine for 
the evaluation of generalized lymphadenopathy. On evalution, 
she was positive for ANA, ds DNA. The excision biopsy of the 
node revealed Non-Hodgkins’ Lymphoma. So this was a 
suspected case of primary pulmonary hypertension which later 
turned out to be a case of SLE with lymphoma. 
 
 All the patients with myocardial dysfunction were 
symptomatic and had exertional dyspnea. All the patients had 
pulmonary congestion and 3 had evidence of systemic venous 
congestion. 
 
Endocarditis and Valvular lesions 
 
 The classical ‘Libman-Sacks’ endocarditis was not seen in 
any of the 45 patients.  
 In fact one patient was referred to the Intensive medical 
care unit of our hospital with florid SLE and she was found to 
have lesions suggestive of Libman-Sacks endocarditis in the 
echo done by the referring physician. Since she had a rapid 
downhill course, we could not include her in the study. 
 
 Mitral valve prolapse with or without MR was the most 
common valvular abnormality in the study. 11 patients had MVP 
which accounted for 24% of the study group. 
 
 Mitral regurgitatation, either associated with MVP or due 
to dilated LV was seen in 8 patients.  
 
Mild AR was seen in 2 patients. 
 
 AR has been the common lesion reported by Doherty and 
Seigel (10). In patients on chronic steroid therapy mitral valve 
was more commonly involved. Along with this, the high 
prevalence of MVP in the general population could have 
accounted for the high prevalence of MVP and MR in this study. 
 
 One patient had TVP with TR. The overall incidence of 
valvular abnormalities is nearly 30% (14 cases).  
 
 Various studies by Nihoyannopoulos  et al (40) have 
shown valvular involvement is common in SLE and it correleates 
with anti-cardiolipin  antibodies. 
 
Hypertension 
 
 Hypertension as defined by JNC VII, SBP >= 140 and or 
DBP >=90mmHg was seen in 6 patients. (i.e,) 15% of the 
patients in the study group. Most of these patients were chronic 
SLE patients on longterm steroid therapy, which could be the 
possible cause. One patient had concomitant renal failure. Two 
cases had evidence of LVH by ECHO. 
Dubois (22) study found the prevalence of  hypertension 
to be 25%. Hypertension in SLE is related to the development 
of nephropathy and to the use of systemic corticosteroids. 
 
ECG abnormalities 
 
 20 patients had ECG abnormalities of which sinus 
tachycardia was most common; seen in one-third of patients. 
Apart from being associated with fever, anemia, overt 
myocardial dysfunction, isolated persistent tachycardia could 
bean early manifestation of myocarditis. 
 
 Inverted T-waves in Inferior leads, consistent with MVP in 
ECHO was seen in 2 out of 11 cases of MVP. 
 LVH (by voltage criteria) was seen in 2 cases. 
 
 Low voltage QRS complexes was seen in 1 case of 
moderate pericardial effusion. 
 
 Diffuse ST-T changes consistent with pericarditis was seen 
in 1 patient, though sinus tachycardia was more frequently 
present in these patients. 
 
 Poor progression of  ‘R’ wave was seen in 1 patient, 
consistent with hypokinesia of  anterior wall in ECHO. 
 
 One case had incomplete RBBB. 
 
 The overall performance of ECG abnormalities in the study 
group is 45%. In a study by Dubois, it was 34% and 74% in a 
study by Badui et al. 
 
 
CONCLUSION 
 
 
 
The study showed cardiovascular involvement in SLE was 
60% (27 patients.) Of these, 55% (15 patients) had symptoms 
that could be attributed to the cardiovascular system. Nearly 
another half were asymptomatic. 
 
In the study, valvular abnormalities was the most 
common manifestation seen in nearly 30% (14 patients). Mitral 
valve prolapse with or without mitral regurgitation was the 
predominant lesion seen in 11 patients. Two patients had trivial 
aortic regurgitation and one had tricuspid valve prolapse with 
tricuspid regurgitation.  
 
Pericarditis was the next common finding documented in 
27% (12 cases), of which the majority were asymptomatic. 
 
Hypertension was seen in 15% of patients and most of 
them were chronic SLE patients on longterm steroid therapy. 
Myocardial dysfunction was seen in less than 10% of the group. 
 
 Thus cardiovascular involvement in SLE is common and 
causes significant morbidity. Thorough evaluation of the 
cardiovascular system is essential for treating a case of SLE 
since it may be masked by other symptoms or the cardiac 
symptoms may be erroneously attributed to disease activity in 
other systems like pulmonary, renal and hematological. 
 
 Since valvular lesions are common in SLE, it is prudent to 
follow prophylaxis for infective endocarditis before dental or 
urological procedures. 
 
In a case of suspected SLE detection of silent pericarditis, 
in the absence of serositis in other sites, helps in  the diagnosis 
of SLE using the criteria. 
 
 
 
 
 
 
 
 
 
PROFORMA 
 
 
CARDIAC MANIFESTATIONS IN SLE 
 
NAME       AGE   SEX  
 
DIAGNOSED SLE IN  : 
 
CLINICAL FEATURES : 
 
SYSTEMIC   - FEVER 
     FATIGUE 
     ANOREXIA 
     WEIGHT LOSS 
     MALAISE 
 
CUTANEOUS  - PHOTOSENSITIVITY 
     MALAR RASH 
     ORAL ULCERS 
     ALOPECIA 
     DISCOID RASH 
 
NEUROLOGICAL  - HEADACHE 
     SEIZURES 
     MOOD / COGNITIVE DISTURBANCE 
     MONO / POLYNEUROPATHY 
     TIA / STROKE 
 
MUSCULOSKELETAL - ARTHRALGIA 
     MYALGIA 
     HAND DEFORMITY 
 
RENAL    - OLIGURIA 
     PEDAL EDEMA 
 
THROMBOSIS  - ARTERIAL 
     VENOUS 
 
RESPIRATORY  - PLEURISY 
     COUGH 
     DYSPNEA 
 
OCULAR   - REDNESS 
     DRY EYES 
 
RELEVANT HISTORY : 
 
SMOKING / ALCHOLIC 
DM  / HT / BA / PT 
ABORTIONS 
 
CURRENTLY ON (Rx) : 
 
    
 
 
 
CLINICAL EXAMINATION : 
 
   PALLOR 
   RASH 
   LYMPHADENOPATHY 
   CLUBBING 
   PEDAL EDEMA 
   PERIORBITAL PUFFINESS 
   ORAL CAVITY 
 
CARDIAC EVALUATION IN DETAIL 
 
SYMPTOMS    SIGNS 
 
CHEST PAIN   PULSE 
DYSPNEA    BP 
PALPITATION   JVP 
SYNCOPE    S1 S2               P2 
PEDAL EDEMA   ADDED SOUNDS 
     
 
 
ECG  
 
 
 
CXR      HRCT 
 
 
ECHO 
 
 
 
 
 
 
 
 
OTHER LAB INVESTIGATIONS 
 
 
HEMOGRAM / PS    BIOCHEMISTRY  URINALYSIS 
 
Hb     UREA 
PCV     SUGAR 
TC     CREATININE 
DC     Na / K 
ESR     LIPID PROFILE 
PLATELETS 
 
BLOOD CULTURE 
 
 
USG ABDOMEN 
 
 
IMMUNOLOGY 
 
 
ANA 
 
dsDNA 
 
CRP 
 
aCL / LAC 
 
 
OTHER INVESTIGATIONS 
 
 
SYSTEMS INVOLVED IN THIS PATIENT/ CRITERIA FOR DIAGNOSIS: 
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 MASTER CHART 
 
 
CARDIACSl. 
No 
Name 
Age 
(in 
Yrs) 
Sex 
Duration 
of  SLE 
(in yrs) Symptoms Signs ECG
1 Ferozkhan 14 M 3/12 Nil Tachycardia Sinu
tachyc
2 Bharathi 27 F 2 Nil Nil WN
3 Jeevitha 15 F 1 Dyspnea  JVP+ 
Tachycardia 
Sinus 
tachyc
Incomp
RBBB 
4 Subathra 22 F 3 Nil Nil WN
5 Sundari  36 F 16 Nil Nil WN
6 Selvi 21 F 3 Nil Nil WN
7 Sankari 22 F 3 Nil Nil WN
8 Ramesh 33 M 1 Dypnea 
palpitation 
Tachycardia Sinu
tachyc
9 Rekha 17 F 2 Palpitation Midsystolic 
click – apex 
ESM+ 
WN
10 Sarasu 23 F 10/12 Chestpain Pericardial 
rub 
Sinu
tachyc
11 Salma 22 F 6/12 Chest pain Pericardial 
rub 
Low 
voltage
Sinus 
tachyc
12 Sumathi 23 F 3/12 Nil Nil Sinu
tachyc
13 Valarmathy 20 F 3/12 Dyspnea 
palpitation 
& pedal 
edema 
JVP+ bibasal 
rales 
Sinu
tachyc
14 Elavarasi 29 F 2 Dyspnea 
palpitation 
& pedal 
edema 
JVP+    Loud 
P2 bibasal 
rales 
Sinu
tachyc
15 Dhanalakshmi 23 F 3/12 Chest pain Pericardial 
rub 
Sinu
tachyc
16 Satya 18 F 1 Nil Nil WN
17 Ramya 25 F 3 Nil Nil WN
18 Uma 34 F 7 Dyspnea BP-160/100 
bibasal rales 
LVH
19 Padma 37 F 10 Nil BP-156/100 WN
20 Muthulakshmi 23 F 3/12 Nil Nil Sinu
tachyc
21 Jeya 40 F 10 Dyspnea 
palpitation 
BP-152/90 LVH
22 Durga 15 F 3/12 Nil Nil WN
23 Bhuvana 27 F 4 Nil BP-140/90 WN
24 Kalaiselvi   14 F 2/12 Nil Nil WN
25 Mala 34 F 4 Nil Nil Sinu
tachyc
26 Rajeswari 32 F 1 Nil Nil WN
27 Selvi 32 F 12 Dysnea   
pedal 
edema 
JVP+ LVS3+ 
bibasal rales 
Sinu
tachyc
PRWP
V4
28 Kannamma 39 F 9 Nil BP-150/100 WN
29 Kalamani 23 F 6/12 Nil Nil WN
30 Mary 28 F 2 Nil Nil T inve
in infe
lead
31 Hemalatha 30 F 5 Palpitation ESM+ Apex WN
32 Gayathri 32 F 3 Nil Nil WN
33 Sridevi 21 F 1 Nil Nil WN
34 Parameswari 34 F 2 Nil Nil T inv
inf.le
35 Gomathy 30 F 3/12 Nil Nil WN
36 Shantha 27 F 3 Dyspnea BP-150/70 Sinu
tachyc
37 Kannan 15 M 1 Nil Nil WN
38 Selvalakshmi 30 F 3 Chestpain 
palpitation 
Pericardial 
rub 
Sinu
tachyc
Diffuse
T chan
39 Neelammal 34 F 6 Nil Nil WN
40 Satyammal 20 F 2 Nil Nil WN
41 Muthammal 23 F 5 Chestpain Ejection 
click+ 
Sinu
tachyc
42 Aswini 19 F 4/12 Nil Nil WN
43 Manimegalai 25 F 2 Nil Nil WN
44 Arun 14 M 3/12 Nil Nil WN
45 Muthu 21 F 1 Nil Nil Sinu
tachyc
 
 
